CVAC
CureVac NVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.05B
P/E Ratio
6.96
EPS
$0.67
Beta
1.84
52W High
$5.72
52W Low
$2.66
50-Day MA
$4.97
200-Day MA
$4.85
Dividend Yield
—
Profit Margin
182.10%
Forward P/E
5.24
PEG Ratio
—
About CureVac NV
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.
Fundamentals
| Revenue (TTM) | $70.74M |
| Gross Profit (TTM) | $65.99M |
| EBITDA | $193.69M |
| Operating Margin | 573.00% |
| Return on Equity | 40.20% |
| Return on Assets | 23.80% |
| Revenue/Share (TTM) | $0.44 |
| Book Value | $5.63 |
| Price-to-Book | 1.03 |
| Price-to-Sales (TTM) | 14.83 |
| EV/Revenue | 7.23 |
| EV/EBITDA | 2.82 |
| Quarterly Earnings Growth (YoY) | 24.00% |
| Quarterly Revenue Growth (YoY) | -89.00% |
| Shares Outstanding | $225.17M |
| Float | $180.77M |
| % Insiders | 0.10% |
| % Institutions | 10.43% |
Data last updated: 4/7/2026